Aug 16, 2022 8:00am EDT QSAM Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Jul 13, 2022 1:32pm EDT QSAM Biosciences Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam®
May 17, 2022 8:00am EDT QSAM Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update
Apr 28, 2022 7:00am EDT QSAM Biosciences Doses First Patient in its Clinical Trial for Cyclosam®, Radiopharmaceutical Drug Candidate for the Treatment of Bone Cancer
Apr 12, 2022 8:00am EDT QSAM Biosciences Receives Japanese Patent for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®
Feb 02, 2022 8:30am EST QSAM Biosciences Receives Rare Pediatric Disease Designation from FDA for CycloSam in the Treatment of Osteosarcoma
Dec 01, 2021 9:00am EST QSAM Biosciences Activates Clinical Sites and Opens Enrollment for its Phase 1 Clinical Trial of CycloSam® for the Treatment of Bone Cancer
Aug 25, 2021 9:00am EDT QSAM Biosciences Announces FDA Clearance of IND for Samarium-153 DOTMP (CycloSam®), an Investigational Radiopharmaceutical for the Treatment of Bone Cancer
